All In Biotech

Drug Trial Radar · NCT02265510

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Apr 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

83

Actual

Start

Sep 10, 2014

Primary completion

Feb 27, 2019

Study completion Feb 27, 2019

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Oct 16, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).

Conditions

  • Solid Tumors
  • Advanced Malignancies
  • Metastatic Cancer

Interventions

  • INCB052793Drug

    Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.

  • gemcitabineDrug

    Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.

  • nab-paclitaxelDrug

    nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.

  • dexamethasoneDrug

    Dexamethasone administered orally at the protocol-specified dose and frequency.

  • CarfilzomibDrug

    Carfilzomib administered intravenously at the protocol-specified dose and frequency.

  • bortezomibDrug

    Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.

  • lenalidomideDrug

    Lenalidomide administered orally at the protocol-specified dose and frequency.

  • azacitidineDrug

    Azacitidine administered subcutaneously at the protocol-specified dose and frequency.

  • INCB052793Drug

    INCB052793 tablets administered orally at the protocol specified dose strength and frequency.

  • pomalidomideDrug

    Pomalidomide administered orally at the protocol-specified dose and frequency.

  • INCB050465Drug

    INCB050465 tablets administered orally at the protocol specified dose strength and frequency.

  • INCB039110Drug

    INCB039110 tablets administered orally at the protocol specified dose strength and frequency.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a and 1b: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)Time frame: From first dose of study drug up to 30 days after last dose of study drug (Up to approximately 3.4 years)
  2. Phase 2: Objective Response Rate (ORR) in Hematological MalignanciesTime frame: Baseline through end of study (Up to approximately 4.5 years)

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    West Hollywood, California

  • Site not named

    New Haven, Connecticut

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Hackensack, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Portland, Oregon

  • Site not named

    Greenville, South Carolina

  • Site 2

    Nashville, Tennessee

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.